Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

NovAliX Appoints CSO

Published: Wednesday, October 17, 2012
Last Updated: Wednesday, October 17, 2012
Bookmark and Share
Appointment of Dr Luc Van Hijfte as CSO drug discovery.

NovAliX has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.

Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery.

He joined from Janssen, a J&J company, where he served as Head of Medicinal Chemistry EU with responsibility over European based chemical sciences and ADMET.

During this tenure, that included responsibility as site head of the Janssen-Cilag Research Center in Val de Reuil, Dr Van Hijfte has been privileged to contribute to several successful projects with numerous programs entering into clinical development in the areas of Neurosciences, Oncology and Infectious Diseases, with compounds up to phase III level, the most advanced being the anti-tuberculosis compound TMC 207 currently being reviewed by the FDA for market authorization.

Prior to that Dr Van Hijfte had responsibilities at Hoechst Marion Roussel, subsequently at Sanofi as Head of chemistry of the Strasbourg research center.

Luc Van Hijfte earned his PhD in organic synthetic chemistry from the University of Gent under the supervision of Pr. M. Vandewalle, and has completed a post-doctoral training at the University of California, Santa Barbara, in the laboratory of Pr. R.D. Little.

Dr Van Hijfte, who is sharing the vision of the company founders, believing in the relevance of biophysical sciences for drug discovery commented, "I have been impressed by the scope and scale of the biophysical technologies NovAliX has assembled. That was a compelling argument to join the company and have the opportunity to run fragment-based discovery programs".

Both, Denis Zeyer, CEO, and Jean-Paul Renaud, CSO Science & Technology, and founding members of the company are enthusiastic about that addition to the team. "This is a defining moment for our company. Since inception, we have been concentrating on the development of our scientific capabilities in chemistry and biophysics, using a combination of internal technology developments and external sourcing including corporate acquisitions and academic collaborations. With Luc Van Hijfte now joining the team, we add significant pharmaceutical research leadership to our small molecule discovery capabilities".

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NovAliX Enters into Alliance with Kyowa Hakko Kirin
Companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
Monday, January 14, 2013
NovAliX and Servier Collaborate in Early Discovery Research Program
Under the terms of Graffinity agreement, a NovAliX subsidiary, will be responsible for the discovery of specific small molecule lead candidates for a novel exploratory target chosen by Servier.
Wednesday, October 10, 2012
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the CBS.
Friday, September 16, 2011
NovAliX and Galapagos Collaborate in Osteoarthritis Discovery Research Program
NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.
Monday, August 29, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos